The estimated Net Worth of William D Clark is at least 1.26 百万$ dollars as of 2 June 2022. Mr. Clark owns over 4,023 units of Genocea Biosciences Inc stock worth over 0$ and over the last 18 years he sold GNCA stock worth over 198,934$. In addition, he makes 1,063,000$ as President、 Chief Executive Officer、 Director at Genocea Biosciences Inc.
William has made over 23 trades of the Genocea Biosciences Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 4,023 units of GNCA stock worth 241$ on 2 June 2022.
The largest trade he's ever made was exercising 295,550 units of Genocea Biosciences Inc stock on 14 December 2009 worth over 97,532$. On average, William trades about 14,688 units every 124 days since 2006. As of 2 June 2022 he still owns at least 304,377 units of Genocea Biosciences Inc stock.
You can see the complete history of Mr. Clark stock trades at the bottom of the page.
William D. Clark serves as President, Chief Executive Officer, Director of the Company. Previously he served as our Chief Business Officer from August 2010 to February 2011. Mr. Clark has served on our Board of Directors since February 2011. Prior to joining our Company, he served as Chief Business Officer at Vanda Pharmaceuticals, Inc. ("Vanda"), a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company’s strategic and business development activities, and played a central role in multiple public and private financings. Prior to Vanda, Mr. Clark was a principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of strategic and commercial roles at SmithKline Beecham (now GlaxoSmithKline). Mr. Clark holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.
As the President、 Chief Executive Officer、 Director of Genocea Biosciences Inc, the total compensation of William Clark at Genocea Biosciences Inc is 1,063,000$. There are no executives at Genocea Biosciences Inc getting paid more.
William Clark is 51, he's been the President、 Chief Executive Officer、 Director of Genocea Biosciences Inc since 2011. There are 9 older and 9 younger executives at Genocea Biosciences Inc. The oldest executive at Genocea Biosciences Inc is George Siber, 75, who is the Independent Director.
William's mailing address filed with the SEC is C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE, MA, 02140.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over 9,875,933$ worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth 259,728,894$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of 0$. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth 81$.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: